中国医药：富马酸伏诺拉生化学原料药获批上市

Core Viewpoint - China Pharmaceutical (600056) announced the approval of its subsidiary Tianfang Pharmaceutical's application for the active pharmaceutical ingredient Fumaric Acid Venlorasine by the National Medical Products Administration, indicating a significant advancement in its product pipeline [1] Group 1: Product Approvals - Tianfang Pharmaceutical received the approval notice for Fumaric Acid Venlorasine, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The company also obtained the European Pharmacopoeia suitability certificate for Clindamycin Phosphate, an antibiotic used for Gram-positive and anaerobic bacterial infections, from the European Medicines Agency [1]